Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.